NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May 9, 2017, Nektar Therapeutics, a Delaware corporation
(Nektar), issued a press release (the Press Release) announcing
itsfinancial results for the quarter ended March 31, 2017. Acopy
of the Press Release is furnished herewith as Exhibit 99.1.
On May 2, 2017, Nektar announced that it would hold a Webcast
conference call on May 9, 2017 to review its financial results
for the quarter ended March 31, 2017. This conference call is
accessible through a link that is posted on the home page and
Investors section of the Nektar website:
http://www.nektar.com.
The information in this report, including the exhibit hereto, is
being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information contained herein and in the accompanying exhibit
shall not be incorporated by reference into any filing with the
Securities and Exchange Commission made by Nektar Therapeutics,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
| Item9.01 | Financial Statements and Exhibits. |
| Exhibit No. | Description | |
| 99.1 |
Press release titled Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 issued by Nektar Therapeutics on May 9, 2017. |
|
About NEKTAR THERAPEUTICS (NASDAQ:NKTR)
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company’s drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection). NEKTAR THERAPEUTICS (NASDAQ:NKTR) Recent Trading Information
NEKTAR THERAPEUTICS (NASDAQ:NKTR) closed its last trading session down -0.39 at 17.54 with 1,586,208 shares trading hands.
